Clinical Trials Browser

Phase 1/2 × Recurrence × inebilizumab × Clear all

NCT02271945 2018-03-12

Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas

Phase 1/2 Completed

10 enrolled 17 charts

Lymphoma, Non-Hodgkin, Recurrence